Mary Tagliaferri, M.D., serves as Chief Medical Officer of Nektar. Dr. Tagliaferri has over 20 years of experience in pharmaceutical drug development in oncology and women’s health that includes extensive regulatory expertise. In her current role, Dr. Tagliaferri provides clinical strategy guidance and oversees medical affairs, key clinical investigator relationships, and medical writing and publication functions for the company. Since joining Nektar in January 2015, she has provided strategic development leadership for the company’s immunooncology portfolio, especially bempegaldesleukin. She serves as Nektar’s strategic development leader for the company’s clinical collaboration with Bristol-Myers Squibb.
Prior to joining Nektar, Dr. Tagliaferri was a clinical and regulatory consultant to InterMune before its acquisition by Roche. She also served as Chief Medical Officer at KangLaiTe USA, a privately-held biotechnology company which develops oncology drug candidates in multiple solid tumor settings. Dr. Tagliaferri was also a Co-Founder and President and Chief Medical Officer of BioNovo, where she led the company’s clinical drug development strategy and global regulatory affairs, data management and biostatistics, and oversaw clinical operations and compliance. Dr. Tagliaferri received the 2012 State of California Woman of the Year award for her advancements of clinical research in women’s health and her mentorship of women in the biotechnology field.
Dr. Tagliaferri received her B.S. degree from Cornell University and her M.D. from the University of California, San Francisco (UCSF).